Startseite Biotechnologie Merck & Co., Inc. (MSD)
M

Merck & Co., Inc. (MSD)

Profil verwaltet von Bizz Id
Vereinigte Staaten

Beschreibung

MSD (Merck & Co., Inc., Rahway, New Jersey) ist ein forschendes Biopharmaunternehmen, das Arzneimittel und Impfstoffe für Mensch und Tier entwickelt. Das Tiergesundheitsgeschäft firmiert als MSD Animal Health. Nicht zu verwechseln mit der Merck KGaA (Darmstadt).

Produkte

18 Produkte
Bezlotoxumab

Brand: Zinplava. Injection, for intravenous use.

Comercializado (agencia no indicada)

Zulassung eingereicht

Fertigarzneimittel

Geprüft am 2026-10-21

Bezlotoxumab: see suppliers →

Clesrovimab

Brand: Enflonsia. Injection, for intramuscular use.

Comercializado (agencia no indicada)

Zulassung eingereicht

Fertigarzneimittel

Geprüft am 2026-10-21

Clesrovimab: see suppliers →

Gocatamig

MK-6070. Multi-specific antibody; TriTAC targeting DLL3. Small cell lung cancer. Phase 2. With Daiichi Sankyo.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

Gocatamig: see suppliers →

Ifinatamab deruxtecan

MK-2400. ADC: anti-B7-H3 IgG1 linked to a topoisomerase I inhibitor. Previously treated extensive-stage SCLC under review in the US; Phase 3 in esophageal and prostate cancer. With Daiichi Sankyo.

Solicitud presentada: EE. UU.

Zulassung eingereicht

Fertigarzneimittel

Geprüft am 2026-10-21

Ifinatamab deruxtecan: see suppliers →

MK-1406 (neuraminidase inhibitor-Fc)

Therapeutic protein/conjugate; neuraminidase inhibitor linked to an Fc fragment. Influenza. Phase 3.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

MK-2214 (anti-tau)

High-affinity anti-tau monoclonal antibody. Alzheimer's disease. Phase 2.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

MK-3120 (Nectin-4 ADC)

ADC; Nectin-4 antibody with topoisomerase I payload. Bladder/prostate cancer. Phase 2.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

MK-8690 (anti-CD30L)

Fully human anti-CD30L monoclonal antibody. Ulcerative colitis. Phase 2.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

MK-8748 (Tie2/VEGF)

Multi-specific antibody; bispecific that activates Tie2 and inhibits VEGF. Neovascular AMD. Phase 2/3.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

Patritumab deruxtecan

MK-1022. ADC; anti-HER3 linked to topoisomerase I inhibitor. Breast cancer in Phase 3; other solid tumors in Phase 2. With Daiichi Sankyo.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

Patritumab deruxtecan: see suppliers →

Pembrolizumab

Brand: Keytruda. Anti-PD-1 monoclonal antibody; intravenous injection. New indications under review in EU/Japan (muscle-invasive bladder, high-risk endometrial, platinum-resistant ovarian cancer); Phase 3 in small cell lung cancer.

Comercializado (agencia no indicada)

Zulassung eingereicht

Fertigarzneimittel

Geprüft am 2026-10-21

Pembrolizumab: see suppliers →

Pembrolizumab (SC)

Brand: Keytruda Qlex. Pembrolizumab and berahyaluronidase alfa; subcutaneous injection. Hematological malignancies in Phase 2.

Comercializado (agencia no indicada)

Zulassung eingereicht

Fertigarzneimittel

Geprüft am 2026-10-21

Pembrolizumab: see suppliers →

Raludotatug deruxtecan

MK-5909. ADC; anti-CDH6 linked to topoisomerase I inhibitor. Ovarian cancer in Phase 3; cervical, endometrial, gastric and lung cancer in Phase 2. With Daiichi Sankyo.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

Raludotatug deruxtecan: see suppliers →

Remigromig

MK-3000. Tri-specific antibody, Wnt pathway agonist. Diabetic macular edema. Phase 3.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

Remigromig: see suppliers →

Sacituzumab tirumotecan

MK-2870. ADC; anti-TROP2 linked to belotecan-derived payload. Bladder, breast, cervical, endometrial, gastric, NSCLC and ovarian cancer in Phase 3. With Sichuan Kelun-Biotech.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

Sacituzumab tirumotecan: see suppliers →

Sotatercept

Brand: Winrevair. Therapeutic protein, activin signaling inhibitor; subcutaneous injection. Pulmonary arterial hypertension (HYPERION) under review in the US; PH due to left heart disease in Phase 2.

Comercializado (agencia no indicada)

Zulassung eingereicht

Fertigarzneimittel

Geprüft am 2026-10-21

Sotatercept: see suppliers →

Tulisokibart

MK-7240. Anti-TL1A monoclonal antibody. Crohn's disease and ulcerative colitis in Phase 3; axial spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis, rheumatoid arthritis and systemic sclerosis in Phase 2.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

Tulisokibart: see suppliers →

Zilovertamab vedotin

MK-2140. ADC; anti-ROR1 linked to MMAE. Hematological malignancies. Phase 3.

In Entwicklung

Fertigarzneimittel

Geprüft am 2026-10-21

Zilovertamab vedotin: see suppliers →

Unternehmen kontaktieren

Registrieren Sie sich kostenlos, um die Kontaktdaten dieses Unternehmens zu sehen.

Registrieren - Kostenlos